Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD

OBJECTIVE: To compare the diagnostic performance of PET with the amyloid ligand Pittsburgh compound B (PiB-PET) to fluorodeoxyglucose (FDG-PET) in discriminating between Alzheimer disease (AD) and frontotemporal lobar degeneration (FTLD). METHODS: Patients meeting clinical criteria for AD (n = 62) a...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Rabinovici, G.D., Rosen, H.J., Alkalay, A., Kornak, J., Furst, A.J., Agarwal, N., Mormino, E.C., O'Neil, J.P., Janabi, M., Karydas, A., Growdon, M.E., Jang, J.Y., Huang, E.J., DeArmond, S.J., Trojanowski, J.Q., Grinberg, L.T., Gorno-Tempini, M.L., Seeley, W.W., Miller, B.L., Jagust, W.J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Lippincott Williams & Wilkins 2011
Pynciau:
Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3236517/
https://ncbi.nlm.nih.gov/pubmed/22131541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e31823b9c5e
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg